More importantly, dual-inhibition therapy initiated after tumor progression in single agent-treated mice was also remarkably effective at inducing tumor regression in large endometrial xenografts resistant to either PIK3CA or pan-ErbB inhibitors (Lopez et al., 2014, Lopez et al., 2015). Here, EGFR is linked to neoplasm.